Recruiting

NemolizumabReal-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

Sponsor:

Galderma R&D

Code:

NCT06988605

Conditions

Atopic Dermatitis

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.

Conditions

Atopic Dermatitis

Study ID

NCT06988605

Start date

Jul 14, 2025

Status verified date

Nov, 2025

Completion date

Nov 30, 2027

Anticipated

Primary completion date

Nov 6, 2026

Anticipated

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Participants who, according to the treating physician's decision and in line with the local package label, start treatment with nemolizumab (Nemluvio®).
Adolescent and adult participants aged >=12 years with moderate-to-severe AD.
Participants who signed the written informed consent form (ICF) or had it signed by their legal representative.

Exclusion Criteria:

Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label.
Participants who received treatment with a drug under clinical development/investigation within 3 months prior to baseline.
Participants who received nemolizumab previously.
Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires.

Study Design

Enrollment

1000 participants

Anticipated

Interventions and Outcome Measures

Arms

Nemolizumab

Participants with moderate-to-severe AD who are receiving nemolizumab (Nemluvio®) in routine clinical practice will be observed for approximately 12 months.

Primary outcome measure

Investigator Global Assessment (IGA) at Month 6 [ Time Frame: At Month 6 ]
Peak Pruritus Numerical Rating Scale (PP NRS) at Month 6 [ Time Frame: At Month 6 ]

Central Contacts and Locations

Central contacts

Galderma Research and Development

817-961-5000 clinical.studies@galderma.com

Locations

Galdrma Investigational Site - 7077

Recruiting

Phoenix, Arizona, United States, 85006-2754

Galderma Investigational Site 7060

Recruiting

Phoenix, Arizona, United States, 85008-3884

Galderma Investigational Site - 8535

Recruiting

Phoenix, Arizona, United States, 85032-2238

Galderma Investigational Site 8224

Recruiting

Fremont, California, United States, 94538-1603

Galderma Investigational Site 8553

Recruiting

Newport Beach, California, United States, 92663-3606

Galderma Investigational Site 7059

Recruiting

Fairfield, Connecticut, United States, 76824

Galderma Investigational Site 7063

Recruiting

Cutler Bay, Florida, United States, 33157

Galderma Investigational Site 7134

Recruiting

Hollywood, Florida, United States, 33021-6748

Galderma Investigational Site 7078

Recruiting

Miami, Florida, United States, 33173

Galderma Investigational Site 7090

Recruiting

St. Petersburg, Florida, United States, 33713-8012

Galderma Investigational Site 7054

Recruiting

Tampa, Florida, United States, 33609-2230

Galderma Investigational Site 7058

Recruiting

Chicago, Illinois, United States, 60641

Galderma Investigational Site 8142

Recruiting

Indianapolis, Indiana, United States, 46250-2041

Galderma Investigational Site 7098

Recruiting

Columbia, Maryland, United States, 21045-2336

Galderma Investigational Site 8012

Recruiting

Glenn Dale, Maryland, United States, 20769-9182

Galderma Investigational Site 7068

Recruiting

Rockville, Maryland, United States, 20850-6243

Galderma Investigational Site 7065

Recruiting

Brighton, Massachusetts, United States, 02135

Galderma Investigationa Site 7104

Recruiting

Milford, Massachusetts, United States, 01757

Galderma Investigational Site 7071

Recruiting

Caledonia, Michigan, United States, 49316-7478

Galderma Investigational Site 7057

Recruiting

Lee's Summit, Missouri, United States, 64064

Galderma Investigational Site 8848

Recruiting

Las Vegas, Nevada, United States, 89144-0518

Galderma Investigational Site 7055

Recruiting

Portsmouth, New Hampshire, United States, 03801-7156

Galderma Investigational Site - Site 7080

Recruiting

Auburn, New York, United States, 13021

Galderma Investigational Site # 7052

Recruiting

East Syracuse, New York, United States, 13057

Galderma Investigational Site - 7051

Recruiting

New York, New York, United States, 10023

Galderma Investigational Site 7109

Recruiting

New York, New York, United States, 10028

Galderma Investigational Site 7081

Recruiting

Dayton, Ohio, United States, 45414-2799

Galderma Investigational Site 7073

Recruiting

Gresham, Oregon, United States, 97030-2923

Galderma Investigational Site 7082

Recruiting

Cedar Park, Texas, United States, 78613-7875

Galderma Investigational Site 8238

Recruiting

Dallas, Texas, United States, 75230-5808

Galderma Investigational Site 7088

Recruiting

Grapevine, Texas, United States, 76051

Galderma Investigational Site 7069

Recruiting

Sugar Land, Texas, United States, 77478-3842

Galderma Investigational Site 8725

Recruiting

Morgantown, West Virginia, United States, 26505-1873

More Information

Sponsor

Galderma R&D

Last update posted

Mar 13, 2026

Last verified

Nov, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Galderma R&D on 2026-03-13.